0001209191-20-007057.txt : 20200205
0001209191-20-007057.hdr.sgml : 20200205
20200205201930
ACCESSION NUMBER: 0001209191-20-007057
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200204
FILED AS OF DATE: 20200205
DATE AS OF CHANGE: 20200205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Belsky Marc
CENTRAL INDEX KEY: 0001382629
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38542
FILM NUMBER: 20580550
MAIL ADDRESS:
STREET 1: FIVE PRIME THERAPEUTICS
STREET 2: TWO CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kezar Life Sciences, Inc.
CENTRAL INDEX KEY: 0001645666
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473366145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-822-5600
MAIL ADDRESS:
STREET 1: 4000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-04
0
0001645666
Kezar Life Sciences, Inc.
KZR
0001382629
Belsky Marc
C/O KEZAR LIFE SCIENCES, INC.
4000 SHORELINE COURT, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
CFO
Common Stock
2020-02-04
4
P
0
15384
2.60
A
15384
D
Common Stock
2000
I
By Trust
Shares were purchased in a public offering of the Issuer at a public offering price of $2.60.
/s/ Marc Belsky
2020-02-05